← Back
Data updated: Jun 28, 2026
MYCOVIA PHARMS
Pharma Pharmaceuticals
MYCOVIA PHARMS is a pharmaceutical company with 1 FDA-approved products.
2022
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules
FDA Novel Drug Designations
(2022) 1 Novel 1 Priority Review 1 Fast Track
See 1 novel approval →
MYCOVIA PHARMS's Key Drugs
MYCOVIA PHARMS's core commercial portfolio centers on VIVJOA — its most strategically important drugs approved in the last 15 years.
MYCOVIA PHARMS's Recent FDA Approvals
New NDA/BLA approvals for MYCOVIA PHARMS over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
MYCOVIA PHARMS's Therapeutic Areas
Disease areas where MYCOVIA PHARMS has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
MYCOVIA PHARMS Pipeline Snapshot
Active clinical trials for MYCOVIA PHARMS across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • VIVJOA leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2022-04-26
- Latest
- 2024-04-11
- Applications
- 1